Welcome to our dedicated page for Merus SEC filings (Ticker: MRUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merus N.V. filings document the company's oncology-antibody business, common-share capital structure, and completed acquisition process involving Genmab. The record includes Form 8-K material-event disclosures for the transaction agreement and completion of an acquisition or disposition of assets, along with disclosures concerning shareholder voting matters, governance matters, and capital-structure changes.
The company’s Form 15-12G records the termination of registration of Merus N.V. common shares under Section 12(g) and suspension of Exchange Act reporting duties under Sections 13 and 15(d). It identifies the common shares with €0.09 nominal value per share, reports zero holders of record as of the certification date, and shows Merus B.V. acting as successor to Merus N.V.
Merus N.V. investors led by Paradigm BioCapital report that they no longer beneficially own any of the company’s common shares. An amended Schedule 13G/A shows Paradigm BioCapital Advisors LP, its general partner, related fund entities, and individual filer Senai Asefaw each reporting 0 common shares and 0.0% of the class as of December 31, 2025.
The group also certifies that any securities referenced were not acquired and are not held to change or influence control of Merus N.V., and are not related to any control-seeking transaction.
Merus N.V. reports insider activity tied to a change in control transaction. The company previously entered into a Transaction Agreement with Genmab A/S and its wholly owned subsidiary, which commenced a tender offer for all issued and outstanding Merus common shares. On December 12, 2025, the purchaser accepted all Shares that were validly tendered and not properly withdrawn at an all-cash price of $97.00 per share, without interest and less applicable withholding taxes, to be paid as soon as practicable after the acceptance time.
In connection with this transaction, multiple employee share options held by Merus’s Chief Financial Officer & PFO, each a right to buy common shares at exercise prices such as $41.65, $36.09, $26.5, $16.09 and $10.04 per share, were cancelled on December 12, 2025. For each option, the holder will receive cash equal to the amount by which the $97.00 Offer Consideration exceeds the option’s exercise price, multiplied by the number of Shares underlying that option, and the form shows 0 derivative securities beneficially owned after these transactions.
A director of Merus N.V. reported the cancellation of multiple share options in connection with a cash tender offer by Genmab. Under a transaction agreement signed on September 29, 2025, Genmab’s wholly owned subsidiary launched an offer for all issued and outstanding Merus common shares and, on December 12, 2025, accepted all shares that were validly tendered at $97.00 per share in cash.
The reporting person held several options to buy Merus common shares with exercise prices between $10.04 and $48.73. Each option was cancelled on December 12, 2025 in exchange for cash equal to the difference between the $97.00 offer price and the option’s exercise price, multiplied by the number of underlying shares. Following these transactions, the reporting person listed no remaining derivative securities related to Merus common shares.
Merus N.V. director filed an insider report related to Genmab A/S's cash tender offer for all of the company’s common shares at $97.00 per share. On December 12, 2025, Genmab’s wholly owned subsidiary accepted all Shares that were validly tendered and not properly withdrawn, with cash consideration to be paid as soon as practicable afterward.
The filing also shows the director’s stock options were cancelled under the transaction agreement in exchange for cash equal to the difference between the $97.00 offer price and each option’s exercise price, multiplied by the number of underlying Shares, leaving no derivative securities beneficially owned.
Merus N.V. reported that a director’s share options were cancelled in connection with a cash tender offer by Genmab A/S for all Merus common shares. The offer, made through a Genmab subsidiary, accepted all shares validly tendered as of December 12, 2025 in exchange for $97.00 per share in cash, before taxes, payable as soon as practicable after that time. The reported options covered 13,193 and 17,688 common shares with exercise prices of $41.6 and $48.73; each option was cancelled for cash equal to the offer price minus the exercise price, multiplied by the number of underlying shares.
Merus N.V. reported that its Chief Operating Officer and General Counsel, Peter Silverman, canceled multiple stock option awards on December 12, 2025. These share options, with exercise prices ranging from $11.16 to $41.65 per share and expirations between 2029 and 2035, now show zero derivative securities beneficially owned after the transactions.
The cancellations are tied to a transaction in which Genmab A/S, through its wholly owned subsidiary Genmab Holding II B.V., commenced a tender offer for all issued and outstanding Merus common shares. As of the “Acceptance Time” on December 12, 2025, the purchaser accepted all validly tendered shares in exchange for cash of $97.00 per share, without interest and less applicable withholding taxes. Each canceled option is being settled for cash equal to the difference between the $97.00 offer price and its exercise price, multiplied by the number of underlying shares.
Merus N.V. reports how its Chief Medical Officer’s equity was treated in connection with a change-of-control transaction involving Genmab. Genmab’s wholly owned subsidiary commenced a tender offer for all issued and outstanding Merus common shares, and on December 12, 2025 accepted all shares that were validly tendered in exchange for a cash payment of $97.00 per share, without interest and less applicable withholding taxes.
On the same date, stock options with exercise prices of $41.65 and $54.45, covering 50,000 and 183,943 Merus common shares respectively, were cancelled under the transaction agreement. In place of these options, the reporting person became entitled to cash equal to the amount by which the $97.00 offer price exceeded each option’s exercise price, multiplied by the number of underlying shares, leaving zero derivative securities from these grants outstanding.
Merus N.V. reported that its president and CEO tendered his indirectly held common shares and had his stock options cancelled in connection with a cash tender offer by a subsidiary of Genmab A/S. Under a transaction agreement dated September 29, 2025, Genmab Holding II B.V. launched an offer for all issued and outstanding Merus common shares, and on December 12, 2025 it accepted all shares validly tendered at $97.00 per share in cash, without interest and less applicable withholding taxes. Family trusts for which the reporting person and his immediate family are the sole beneficiaries tendered all of their Merus common shares, leaving zero indirect beneficial ownership. On the same date, several option awards with exercise prices between $13.52 and $41.65 per share were cancelled in exchange for cash equal to their in‑the‑money value based on the $97.00 offer price.
Merus N.V. director reports the cancellation of multiple stock option awards in connection with Genmab’s cash tender offer for all Merus common shares at $97.00 per share.
Under a transaction agreement with Genmab A/S and its subsidiary Genmab Holding II B.V., the purchaser accepted all validly tendered Merus shares on December 12, 2025 and will pay the cash consideration without interest, less applicable withholding taxes.
Several “share option (right to buy)” positions with exercise prices ranging from $16.09 to $48.73 and expirations between 2030 and 2035 were disposed of on December 12, 2025. Each option is being converted into cash equal to the excess of the $97.00 offer price over its exercise price, multiplied by the number of underlying common shares, leaving the director with zero of these options after the transaction.